Authors and publish time | Virology and immunologic response | Serious drug- related AEs | ||
---|---|---|---|---|
Experiment group, Â % (n/N) | Control group, n (%) | Experiment group, n (%) | Control group, n (%) | |
Jan van Lunzen et al. 2012. [20] | 10Â mg: 91Â % (48/53) 25Â mg: 88Â % (45/51) 50Â mg: 90Â % (46/5150) | EFV (600Â mg): 82Â % (41/50) | 0 | 2Â % (1/50) |
Pedro Cahn et al. 2013. [23] | 50Â mg: 71Â % (251/354,378) | RAL (400Â mg): 64Â % (230/414) | 1Â % (2/378) | 1Â % (4/414) |
Francois Raffi et al. 2013. [21] | 50Â mg: 88Â % (361/411) | RAL (400Â mg): 85Â % (351/411) | <1Â % (3/411) | 1Â % (5/411) |
S. Walmsley et al. 2013. [22] | 50Â mg: 88Â % (364/414) | RAL (400Â mg): 81Â % (338/419) | <1Â % (1/414) | 2Â % (8/419) |